<DOC>
	<DOC>NCT00433225</DOC>
	<brief_summary>The purpose of this study was to evaluate the efficacy of ketorolac 0.4% on quality of vision and macula thickening in patients undergoing cataract surgery using the ReStor® multifocal IOL.</brief_summary>
	<brief_title>Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation</brief_title>
	<detailed_description />
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Males or females &gt; 50 years old Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL. Likely to complete all study visits and able to provide informed consent Visual potential of 20/25 or better · Prior use of topical ketorolac Known contraindications to any study medication or ingredients Active ocular diseases or uncontrolled systemic disease Active ocular allergies</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>